Brokerages Anticipate Catalyst Biosciences Inc (CBIO) Will Announce Earnings of -$0.59 Per Share

Equities research analysts expect Catalyst Biosciences Inc (NASDAQ:CBIO) to report earnings of ($0.59) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Catalyst Biosciences’ earnings. Catalyst Biosciences posted earnings per share of ($0.96) during the same quarter last year, which indicates a positive year-over-year growth rate of 38.5%. The business is expected to issue its next quarterly earnings results on Thursday, March 7th.

On average, analysts expect that Catalyst Biosciences will report full-year earnings of ($2.27) per share for the current year. For the next financial year, analysts expect that the company will report earnings of ($2.86) per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that that provide coverage for Catalyst Biosciences.

Catalyst Biosciences (NASDAQ:CBIO) last released its quarterly earnings results on Friday, November 2nd. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.59) by ($0.05). Catalyst Biosciences had a negative net margin of 2,983.40% and a negative return on equity of 22.67%.

Separately, Zacks Investment Research lowered shares of Catalyst Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, August 8th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $19.83.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Wells Fargo & Company MN boosted its stake in Catalyst Biosciences by 148.3% during the first quarter. Wells Fargo & Company MN now owns 8,940 shares of the biopharmaceutical company’s stock worth $231,000 after acquiring an additional 5,340 shares in the last quarter. Kalos Management Inc. bought a new position in shares of Catalyst Biosciences in the second quarter valued at $244,000. Quantitative Systematic Strategies LLC bought a new position in shares of Catalyst Biosciences in the second quarter valued at $120,000. Rhumbline Advisers bought a new position in shares of Catalyst Biosciences in the second quarter valued at $136,000. Finally, Northern Trust Corp lifted its stake in shares of Catalyst Biosciences by 91.0% in the first quarter. Northern Trust Corp now owns 25,556 shares of the biopharmaceutical company’s stock valued at $659,000 after buying an additional 12,178 shares in the last quarter. 70.05% of the stock is currently owned by institutional investors and hedge funds.

CBIO stock opened at $11.20 on Friday. The stock has a market cap of $129.58 million, a price-to-earnings ratio of -1.50 and a beta of 2.36. Catalyst Biosciences has a 52-week low of $4.49 and a 52-week high of $37.00.

About Catalyst Biosciences

Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.

Featured Story: What is Considered a Good Return on Equity (ROE)?

Get a free copy of the Zacks research report on Catalyst Biosciences (CBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Catalyst Biosciences (NASDAQ:CBIO)

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply